Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 10.3
(-8.04%)
SEK 10.3
(-8.04%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 203 Thousand SEK | 363.47% |
| 2022 | 43.8 Thousand SEK | -59.26% |
| 2021 | 107.52 Thousand SEK | -72.78% |
| 2020 | 394.94 Thousand SEK | 0.0% |
| 2018 | 664 Thousand SEK | 76.6% |
| 2017 | 376 Thousand SEK | 8.22% |
| 2016 | 347.44 Thousand SEK | -14.83% |
| 2015 | 407.93 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 201 Thousand SEK | -0.99% |
| 2024 Q2 | 201 Thousand SEK | 0.0% |
| 2023 Q4 | 203 Thousand SEK | 0.0% |
| 2023 FY | 203 Thousand SEK | 363.47% |
| 2023 Q3 | 203 Thousand SEK | 30.97% |
| 2023 Q2 | 155 Thousand SEK | -1.95% |
| 2023 Q1 | 158.08 Thousand SEK | 260.91% |
| 2022 Q4 | 43.8 Thousand SEK | -76.43% |
| 2022 Q3 | 185.84 Thousand SEK | 150.32% |
| 2022 FY | 43.8 Thousand SEK | -59.26% |
| 2022 Q2 | 74.24 Thousand SEK | -0.43% |
| 2022 Q1 | 74.56 Thousand SEK | -30.65% |
| 2021 FY | 107.52 Thousand SEK | -72.78% |
| 2021 Q2 | 296.1 Thousand SEK | -9.23% |
| 2021 Q1 | 326.21 Thousand SEK | -17.4% |
| 2021 Q4 | 107.52 Thousand SEK | -40.49% |
| 2021 Q3 | 180.67 Thousand SEK | -38.98% |
| 2020 Q3 | 545.26 Thousand SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 394.94 Thousand SEK | 0.0% |
| 2020 Q4 | 394.94 Thousand SEK | -27.57% |
| 2019 Q3 | 664 Thousand SEK | 0.0% |
| 2018 FY | 664 Thousand SEK | 76.6% |
| 2017 FY | 376 Thousand SEK | 8.22% |
| 2016 FY | 347.44 Thousand SEK | -14.83% |
| 2015 FY | 407.93 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AroCell AB (publ) | 6.07 Million SEK | 96.656% |
| Devyser Diagnostics AB (publ) | 20.6 Million SEK | 99.015% |
| Immunovia AB (publ) | 1.00 SEK | -20299900.0% |
| SenzaGen AB | 6.22 Million SEK | 96.741% |
| Spermosens AB | -232 Thousand SEK | 187.5% |